# EDGAR Filing Document

**Accession Number:** 0001661998
**File Stem:** 0000000000-23-002466
**Filing Date:** 2023-3
**Character Count:** 2343
**Document Hash:** 3516a9a415020f38caf5808d96340441
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002466.hdr.sgml**: 20230414

**ACCESSION NUMBER**: 0000000000-23-002466

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230314

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Homology Medicines, Inc.
- **CENTRAL INDEX KEY:** 0001661998
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 473468154
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** ONE PATRIOTS PARK
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
- **BUSINESS PHONE:** 781-301-7277

**MAIL ADDRESS:**
- **STREET 1:** ONE PATRIOTS PARK
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-23-066165

## Text-Extract

```

United States securities and exchange commission logo

                          March 14, 2023

       Paul Alloway
       General Counsel
       Homology Medicines, Inc.
       One Patriots Park
       Bedford, Massachusetts 01730

                                                        Re: Homology Medicines,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed March 9, 2023
                                                            File No. 333-270414

       Dear Paul Alloway:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Arzhang
Navai at 202-551-4676 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Wesley Holmes

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._